Sabarni Sarker, Md. Ashraf Ali, R. Barman, Shuji Noguchi, Y. Iwao, S. Itai, M. I. I. Wahed
{"title":"Preparation and Antidiabetic Effect of Orally Administered Nifedipine‐Loaded Solid Lipid Nanoparticles in Fructose-Induced Diabetic Rats","authors":"Sabarni Sarker, Md. Ashraf Ali, R. Barman, Shuji Noguchi, Y. Iwao, S. Itai, M. I. I. Wahed","doi":"10.4236/PP.2018.910035","DOIUrl":null,"url":null,"abstract":"The use of Nifedipine (NI), a dihydropyridine \ncalcium channel blocker, is limited due to its \npoor aqueous solubility. However, NI loaded solid-lipid nanoparticles (NI-SLN) \nare known to exhibit suitable pharmacokinetic properties and good \nbiocompatibility. The present investigation was designed to evaluate the \neffects of NI-SLN on glucose homeostasis, lipid metabolism and liver function \nin fructose-induced diabetic rats. NI-SLN was prepared by high pressure \nhomogenization technique followed by lyophilization with trehalose as \ncryoprotectant. Diabetes was induced into rats by the administration of \nfructose (10%) in drinking water for six weeks. After induction of diabetes, \nrats were divided into four groups for the oral ingestion of NI, NI-SLN and/or \nvehicles and their effects on blood glucose levels, oral glucose tolerance test \n(OGTT), lipid profile, biochemical parameters, electrolytes and histopathology \nwere observed. Single dose administration and treatment with NI-SLN showed \nsignificant glucose lowering efficacy in fructose-induced diabetic rats. \nAlthough NI and NI-SLN did not alter the fasting blood glucose level in normal \nrats, diabetic rats treated with NI-SLN resulted in significant reduction in \nglucose level for 24 hr. In OGTT, NI-SLN exhibited significant \nantihyperglycemic activity in both normal and diabetic rats. So, NI-SLN has \nbetter glucose lowering efficacy than that of pure NI in diabetic rats. The \nsurvival rates in rats among the treatment groups were 100%. Treatment with \nNI-SLN significantly improved lipid profiles than NI alone and the effect was \ndose-dependent. Administration of NI-SLN significantly reduced uric acid, \ncreatinine levels and maintained a good cationic balance. After two weeks of \nNI-SLN treatment, hepatocytes regained their \nnormal architecture, and the beneficial effect could be correlated with the reduction of SGOT and total bilirubin levels. \nTherefore, NI-SLN was found to be \nuseful for the enhancement of bioavailability and exhibited profound \nantidiabetic activity in rats. The results of the study suggested that \nNI-SLN exerted better improvement in glucose levels, lipid profiles and organ \nprotection than pure NI and might have some beneficial effects in the \nmanagement of diabetic patients.","PeriodicalId":19875,"journal":{"name":"Pharmacology & Pharmacy","volume":"100 1","pages":"457-471"},"PeriodicalIF":0.0000,"publicationDate":"2018-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/PP.2018.910035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4
Abstract
The use of Nifedipine (NI), a dihydropyridine
calcium channel blocker, is limited due to its
poor aqueous solubility. However, NI loaded solid-lipid nanoparticles (NI-SLN)
are known to exhibit suitable pharmacokinetic properties and good
biocompatibility. The present investigation was designed to evaluate the
effects of NI-SLN on glucose homeostasis, lipid metabolism and liver function
in fructose-induced diabetic rats. NI-SLN was prepared by high pressure
homogenization technique followed by lyophilization with trehalose as
cryoprotectant. Diabetes was induced into rats by the administration of
fructose (10%) in drinking water for six weeks. After induction of diabetes,
rats were divided into four groups for the oral ingestion of NI, NI-SLN and/or
vehicles and their effects on blood glucose levels, oral glucose tolerance test
(OGTT), lipid profile, biochemical parameters, electrolytes and histopathology
were observed. Single dose administration and treatment with NI-SLN showed
significant glucose lowering efficacy in fructose-induced diabetic rats.
Although NI and NI-SLN did not alter the fasting blood glucose level in normal
rats, diabetic rats treated with NI-SLN resulted in significant reduction in
glucose level for 24 hr. In OGTT, NI-SLN exhibited significant
antihyperglycemic activity in both normal and diabetic rats. So, NI-SLN has
better glucose lowering efficacy than that of pure NI in diabetic rats. The
survival rates in rats among the treatment groups were 100%. Treatment with
NI-SLN significantly improved lipid profiles than NI alone and the effect was
dose-dependent. Administration of NI-SLN significantly reduced uric acid,
creatinine levels and maintained a good cationic balance. After two weeks of
NI-SLN treatment, hepatocytes regained their
normal architecture, and the beneficial effect could be correlated with the reduction of SGOT and total bilirubin levels.
Therefore, NI-SLN was found to be
useful for the enhancement of bioavailability and exhibited profound
antidiabetic activity in rats. The results of the study suggested that
NI-SLN exerted better improvement in glucose levels, lipid profiles and organ
protection than pure NI and might have some beneficial effects in the
management of diabetic patients.